Alphabet's Subsidiary Raises $2.1B to Accelerate Clinical Trials of AI-Developed Drugs

Isomorphic Labs, an AI-driven drug discovery company led by Demis Hassabis (co-founder of Alphabet), recently announced a $2.1 billion Series B funding round. The round was led by Thrive Capital, with participation from Alphabet and several sovereign wealth funds, with the goal of advancing AI-discovered drug candidates into clinical trials.
Founded in 2021 and headquartered in London, the company is dedicated to redefining drug discovery through artificial intelligence. This investment not only sets a new record in the field but also reflects strong market confidence in AI's ability to tackle major human health challenges.
Advancing the IsoDDE Smart Platform
The funding will be used to expand the company's internal AI development platform, IsoDDE, and to grow its global talent team. The platform integrates multiple proprietary AI models that operate across various therapeutic areas and drug classes, significantly shortening the early stages of drug development.
Hassabis noted that the company's core R&D approach has been validated, and the current priority is to scale the technology. By combining reliable research data with efficient AI algorithms, the ambitious mission of "solving all diseases" is gradually moving from vision to reality.
Strengthening Partnerships with Pharmaceutical Giants
Isomorphic Labs has formed deep partnerships with leading global pharmaceutical companies, including Novartis, Eli Lilly, and Johnson & Johnson. Through shared technology platforms and R&D pipelines, these industry leaders are using AI to overcome the traditional drug development bottleneck of high costs and low yields.
Industry experts view this funding as a pivotal moment for AI-driven drug discovery as it enters clinical validation. As more AI-developed drugs move into clinical trials, the healthcare sector is poised for a computing-powered efficiency revolution, offering renewed hope for patients worldwide.
Related article
Microsoft Unveils MAI-Transcribe-2, Its Most Accurate Transcription Model Yet, Supporting 60 Languages at Just 0.67 Yuan Per Hour
Microsoft has launched MAI-Transcribe-2, positioning it as the industry’s fastest, most precise, and cost-efficient AI speech-to-text solution. Priced at a promotional rate of $0.10 (approx. 0.67 RMB) per hour, this offer remains valid through the en
Tencent Accelerates AI Push With Doubled-Size Hunyuan Hy4, Morgan Stanley Lifts Target to HKD 550
Tencent has officially unveiled the preview of HuanYuan Hy4, accelerating its timeline ahead of Morgan Stanley’s September forecast and fulfilling the company’s Q2 earnings commitment to launch the model within the year. Since appointing Yao Shunyu a
Pearson’s Dave Treat: AI Should Guide Learning, Not Cheat
Pearson’s Chief Technology Officer, Dave TreatOn academic integrity, AI adoption, and the critical skills that matter as agentic AI transforms educationDave Treat joined Pearson nearly two years ago as Chief Technology Officer, later assuming the rol
Related Special Topic Recommendations
Comments (1)
0/500

Isomorphic Labs, an AI-driven drug discovery company led by Demis Hassabis (co-founder of Alphabet), recently announced a $2.1 billion Series B funding round. The round was led by Thrive Capital, with participation from Alphabet and several sovereign wealth funds, with the goal of advancing AI-discovered drug candidates into clinical trials.
Founded in 2021 and headquartered in London, the company is dedicated to redefining drug discovery through artificial intelligence. This investment not only sets a new record in the field but also reflects strong market confidence in AI's ability to tackle major human health challenges.
Advancing the IsoDDE Smart Platform
The funding will be used to expand the company's internal AI development platform, IsoDDE, and to grow its global talent team. The platform integrates multiple proprietary AI models that operate across various therapeutic areas and drug classes, significantly shortening the early stages of drug development.
Hassabis noted that the company's core R&D approach has been validated, and the current priority is to scale the technology. By combining reliable research data with efficient AI algorithms, the ambitious mission of "solving all diseases" is gradually moving from vision to reality.
Strengthening Partnerships with Pharmaceutical Giants
Isomorphic Labs has formed deep partnerships with leading global pharmaceutical companies, including Novartis, Eli Lilly, and Johnson & Johnson. Through shared technology platforms and R&D pipelines, these industry leaders are using AI to overcome the traditional drug development bottleneck of high costs and low yields.
Industry experts view this funding as a pivotal moment for AI-driven drug discovery as it enters clinical validation. As more AI-developed drugs move into clinical trials, the healthcare sector is poised for a computing-powered efficiency revolution, offering renewed hope for patients worldwide.
Microsoft Unveils MAI-Transcribe-2, Its Most Accurate Transcription Model Yet, Supporting 60 Languages at Just 0.67 Yuan Per Hour
Microsoft has launched MAI-Transcribe-2, positioning it as the industry’s fastest, most precise, and cost-efficient AI speech-to-text solution. Priced at a promotional rate of $0.10 (approx. 0.67 RMB) per hour, this offer remains valid through the en
Tencent Accelerates AI Push With Doubled-Size Hunyuan Hy4, Morgan Stanley Lifts Target to HKD 550
Tencent has officially unveiled the preview of HuanYuan Hy4, accelerating its timeline ahead of Morgan Stanley’s September forecast and fulfilling the company’s Q2 earnings commitment to launch the model within the year. Since appointing Yao Shunyu a
Pearson’s Dave Treat: AI Should Guide Learning, Not Cheat
Pearson’s Chief Technology Officer, Dave TreatOn academic integrity, AI adoption, and the critical skills that matter as agentic AI transforms educationDave Treat joined Pearson nearly two years ago as Chief Technology Officer, later assuming the rol





Home






